<DOC>
	<DOC>NCT01028040</DOC>
	<brief_summary>This is a single centre, open label, non-randomised study to access the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD3043 following a single dose administration to Japanese subjects.</brief_summary>
	<brief_title>AZD Single Ascending Dose Study In Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy Japanese male and females of nonchildbearing potential aged ≥20 to ≤ 45 with suitable veins for cannulation or repeated venepuncture. Body weight 4590 kg and Body mass index (BMI) ≥18.0 and ≤27.0 kg/m2 Clinically normal physical findings including supine blood pressure, pulse rate, ECG, and laboratory assessments in relation to age, as judged by the Investigator. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs Any clinically significant illness/infection or medical/surgical procedure or trauma, as judged by the Principal Investigator, within 4 weeks of the first administration of investigational product. Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Phase I</keyword>
	<keyword>AZD3043</keyword>
	<keyword>Japanese healthy volunteer</keyword>
</DOC>